• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Turkey·Basic Materials·HEKTS.IS
Share

Hektas Ticaret T.A.S. Stocks

TRY 2.84Last Updated 27.08.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

TRY 500.69M

TRY 2.84
Key Takeaways

Risk factor

Weak & very vulnerable to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Hektas Ticaret T.A.S., founded in 1956 and headquartered in Gebze, Turkey, is a leading Turkish company that manufactures, imports, and distributes a wide spectrum of agricultural and veterinary products. For the agricultural sector, their offerings include an extensive range of crop protection solutions such as fungicides, herbicides, insecticides, acaricides, biological insecticides, fumigants, nematicides, soil fumigants, and plant growth regulators. They also provide specialized winter care treatments, summer oils, and spreading agents. Furthermore, Hektas supplies various fertilizers, including foliar applications, organo-mineral compounds, and drip irrigation products, alongside other farming essentials and even tomato seeds. In the animal health domain, the company offers a diverse portfolio of veterinary pharmaceuticals, encompassing antibacterials, vitamin and mineral supplements, feed additives, anti-inflammatory drugs, and anti-parasitics. Their product line additionally features poultry health remedies, pet care items, and pet food.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of HEKTS.IS is 4.30 and suggests 51.4% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.08.2026 17:55

Claude Has Entered the Real World: Anthropic Has Released an AI That Controls Lasers and Robotic Arms

28.08.2026 17:18

"Hot Potato": Why Burry is Bearish on Build-A-Bear Stock

28.08.2026 16:45

Wendy's stock plummeted after Nelson Peltz's fund decided not to buy the company

28.08.2026 16:15

Gold mining stocks outperformed chipmakers' stocks in August. Who's in the black?

28.08.2026 15:50

Morgan Stanley saw a "unique opportunity" in SpaceX shares after their plunge

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026